<article>
<section>
<h1 id="header">Detection of SARS-CoV-2 spike protein binding to ACE2 in living cells by TR-FRET</h1>
<p><time datetime="2021-12-17">Published: December 17, 2021</time></p>
<p>Erika Cecon,<sup><a href="#aff1">1</a>,<a href="#fn1">2</a>,<a href="#cor1">*</a></sup> Julie Dam,<sup><a href="#aff1">1</a></sup> and Ralf Jockers<sup><a href="#aff1">1</a>,<a href="#fn2">3</a>,<a href="#cor2">**</a></sup></p>
<p id="aff1"><sup>1</sup>Université de Paris, Institut Cochin, INSERM, CNRS, 75014 Paris, France</p>
<p id="fn1"><sup>2</sup>Technical contact</p>
<p id="fn2"><sup>3</sup>Lead contact</p>
<p id="cor1"><sup>*</sup>Correspondence: <a href="mailto:erika.cecon@inserm.fr">erika.cecon@inserm.fr</a></p>
<p id="cor2"><sup>**</sup>Correspondence: <a href="mailto:ralf.jockers@inserm.fr">ralf.jockers@inserm.fr</a></p>
<p><span class="open-access">Open Access</span> • DOI: <a href="https://doi.org/10.1016/j.xpro.2021.101024">10.1016/j.xpro.2021.101024</a></p>
</section>
<section>
<h2 id="summary">Summary</h2>
<p>The SARS-CoV-2 coronavirus infects human cells through the interaction of the viral envelope spike protein (IPR044366) with the human angiotensin-converting enzyme 2 (ACE2), expressed at the surface of target cells. Here, we describe a detailed protocol to measure the binding of the receptor binding domain (RBD) of spike to ACE2 by time-resolved fluorescence resonance energy transfer (TR-FRET). The assay detects the spike/ACE2 interaction in physiologically relevant cellular contexts and is suitable for high-throughput investigation of interfering small-molecule compounds and antibodies.</p>
<p>For complete details on the use and execution of this protocol, please refer to <a class="external-link" href="https://doi.org/10.1016/j.chembiol.2021.06.008">Cecon et al. (2021)</a>.</p>




<div class="highlights">
<h3>Highlights</h3>
<ul>
<li>Quantitative detection of SARS-CoV-2 spike interaction with ACE2 in living cells</li>
<li>High-throughput-compatible assay suitable for screening of inhibitory molecules</li>
<li>Suitable to investigate the impact of membrane components on ACE2/spike complex</li>
</ul>
</div>
<div class="graphical-abstract">
<h3>Graphical abstract</h3>
<figure><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/1243-GA.jpg" alt="GraphicalAbstract.jpg"></figure>
</div></section>
<section>
<h2 id="before-you-begin">Before you begin</h2>
<p>The protocol below describes the specific steps of the Spike/ACE2 binding assay in Human Embryonic Kidney 293 Cells (HEK293T) cells based on the TR-FRET technique to screen for inhibitory compounds. The assay is compatible with any cell type provided that the cells can be transfected to express the SNAP-tagged human ACE2 fusion protein. The TR-FRET assay is based on the energy transfer between an energy donor and energy acceptor that occurs if they are in close proximity to each other (less than 10 nm) (<a href="#bib5">Mathis, 1995</a>; <a href="#bib1">Bazin et al., 2002</a>; <a href="#bib3">Degorce et al., 2009</a>). Distinctively from classical FRET, the Time-Resolved (TR) aspect of the TR-FRET uses special donor fluorophores from the lanthanide family, displaying extended lifetime emission properties, which allows the introduction of a time delay between donor excitation and FRET signal measurement. This time-resolved feature results in measurement of the FRET signal at a time window of lowest background, following the decay of non-specific transient fluorescence signals, providing thus improved signal-to-noise ratio. This protocol uses the receptor binding domain (RBD) of the SARS-CoV-2 Spike protein labeled with the d2 fluorophore (energy acceptor, emission at 665 nm) and the human ACE2 labeled with the terbium-cryptate fluorophore (energy donor; excitation at 320-340 nm, <a href="#tbl1">Table 1</a>) to monitor the proximity between RBD and ACE2 through the resulting TR-FRET signal.</p>
<p>The protocol describes a high-throughput(HT)-compatible assay format, but it can also be performed in a low-throughput format.</p>
<div class="note">
<span class="note-title">Note:</span> The advantage of performing the TR-FRET assay in the low-throughput / adherent cell format is that it allows to treat the cells for long incubation time with compounds (<i>i.e.</i> 16–24 h incubation).</div>
<p>A list of all reagents, buffer and equipment for this protocol are described in the <a href="#key-resources-table">key resources table</a> and <a href="#materials-and-equipment">materials and equipment</a> sections. Make sure all materials required for the experiments are available and/or prepared in advance.</p>
<div class="note">
<span class="note-title">Note:</span> The experimental design should be established in advance in order to calculate the precise volume needed of each reagent. Please refer to <a href="#tbl2">Table 2</a> for the volumes required per well.</div>
<h3 id="sec1.1">Cell culture</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 2–7 days</div>
<ol>
<li>Thaw an aliquot of HEK293T cells and immediately plate the cells in 10 cm cell culture dishes containing complete culture medium.</li>
<li>HEK293T cells are cultured in Dulbecco’s modified Eagle’s medium (DMEM) with high glucose and supplemented with 1% Streptomycin/Penicillin and 10% fetal bovine serum, at 37°C, 5% CO<sub>2</sub>.
<ol type="a">
<li>Cells are cultured in 10 cm cell culture dishes, and they are split in cell culture medium twice per week at a 1:10 ratio.</li>
<li>Culture cells for at least 5–7 days after thawing before using them for transfection to ensure they are healthy.</li>
</ol>
</li>
</ol>
<div class="critical">
<span class="critical-title">Critical:</span> Cells should be constantly inspected and tested for mycoplasma contamination. Several kits for mycoplasma detection are commercially available, such as PlasmoTest kit (cat. Rep-pt1, InvivoGen, France; <a href="https://www.invivogen.com/plasmotest">https://www.invivogen.com/plasmotest</a>) or MycoSEQ kit (ThermoFisher Scientific, Waltham, USA; <a href="https://www.thermofisher.com/document-connect/document-connect.html?url=https://assets.thermofisher.com/TFS-Assets%2FLSG%2Fmanuals%2F4465874.pdf">https://www.thermofisher.com/document-connect/document-connect.html?url=https://assets.thermofisher.com/TFS-Assets%2FLSG%2Fmanuals%2F4465874.pdf</a>).</div>
<h3 id="sec1.2">Experimental design</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 30 min</div>
<ol start="3">
<li>In order to calculate the amounts of reagents required for the experiment, the experimental plate design needs to be set in advance. The data points should be performed in triplicates and it <b>should always</b> include the following groups: <b>i.</b> background (“BKG” - absence of d2-labelled RBD); <b>ii.</b> total binding (“TB” - presence of d2-labelled RBD); <b>iii.</b> non-specific binding (“NSB” - presence of RBD-d2 AND excess of non-labelled RBD); <b>iv.</b> test (total binding of RBD-d2 in the presence of a compound to be tested for its effect on the RBD/ACE2 interaction). <a href="#fig1">Figure 1</a> shows an example of plate template.
<figure id="fig1"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/1243-Fig1.jpg" alt="Fig1.jpg">
<figcaption>
<div class="figcaption-title">Figure 1. Example of plate template</div>
<p>Example of an experiment comprising the three mandatory groups background (“BKG”), total binding (“TB”) and non-specific binding (“NSB”), as well as 16 test compounds (T1-T16, distributed horizontally) at 6 different concentrations each (C1-C6, distributed vertically).</p>
</figcaption>
</figure>
</li>
</ol>
</section>
<section>
<h2 id="key-resources-table">Key resources table</h2>
<table id="krt">
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3">Chemicals, peptides, and recombinant proteins</td>
</tr>
<tr>
<td>SARS-CoV-2 spike RBD protein</td>
<td>Sino Biological</td>
<td>Cat# 40592-V08H</td>
</tr>
<tr>
<td>SARS-CoV-2 spike S1-S2 protein</td>
<td>Sino Biological</td>
<td>Cat# 40589-V08B1</td>
</tr>
<tr>
<td>d2-labelled SARS-CoV-2 spike RBD protein</td>
<td><a href="#bib2">Cecon et al., 2021</a></td>
<td>N/A</td>
</tr>
<tr>
<td>d2-labelled SARS-CoV-2 spike S1-S2 protein</td>
<td><a href="#bib2">Cecon et al., 2021</a></td>
<td>N/A</td>
</tr>
<tr>
<td>Terbium cryptate Lumi4-Tb</td>
<td>Cisbio Bioassays</td>
<td>Cat# SSNPTBX</td>
</tr>
<tr>
<td>TagLite labelling medium</td>
<td>Cisbio Bioassays</td>
<td>Cat# LABMED</td>
</tr>
<tr>
<td>jetPEI transfection reagent</td>
<td>Polyplus-transfection</td>
<td>Cat# 101-10N</td>
</tr>
<tr>
<td>Cell Dissociation Solution Non-Enzymatic</td>
<td>Sigma-Aldrich</td>
<td>Cat# C5789</td>
</tr>
<tr>
<td>Dulbecco’s modified Eagle’s medium (DMEM)-Glutamax</td>
<td>Life Technologies</td>
<td>Cat# 31966047</td>
</tr>
<tr>
<td>TRYPSIN 0.25% EDTA</td>
<td>Life Technologies</td>
<td>Cat# 25300096</td>
</tr>
<tr>
<td>Penicillin/streptomycin</td>
<td>Life Technologies</td>
<td>Cat# 15140130</td>
</tr>
<tr>
<td>Trypan blue solution</td>
<td>Sigma-Aldrich</td>
<td>Cat# T8154</td>
</tr>
<tr>
<td>PlasmoTest kit</td>
<td>InvivoGen</td>
<td>Cat# Rep-pt1</td>
</tr>
<tr>
<td>10× phosphate buffered saline (PBS)</td>
<td>Life Technologies</td>
<td>Cat# 14040174</td>
</tr>
<tr>
<td colspan="3">Experimental models: Cell lines</td>
</tr>
<tr>
<td>Human: Human Embryonic Kidney (HEK) 293 cells</td>
<td>Sigma-Aldrich</td>
<td>RRID:CVCL_0063</td>
</tr>
<tr>
<td colspan="3">Recombinant DNA</td>
</tr>
<tr>
<td>SNAP-ACE2 plasmid</td>
<td><a href="#bib2">Cecon et al., 2021</a></td>
<td>Addgene id:178592</td>
</tr>
<tr>
<td colspan="3">Software and algorithms</td>
</tr>
<tr>
<td>Image J</td>
<td><a href="#bib6">Schneider et al., 2012</a></td>
<td>RRID: SCR_003070<a href="https://imagej.nih.gov/ij/download.html">https://imagej.nih.gov/ij/download.html</a>
</td>
</tr>
<tr>
<td>GraphPad Prism 6</td>
<td>GraphPad Software Inc</td>
<td>RRID: SCR_002798<a href="https://www.graphpad.com/scientific-software/prism/">https://www.graphpad.com/scientific-software/prism/</a>
</td>
</tr>
<tr>
<td colspan="3">Other</td>
</tr>
<tr>
<td>Cell culture incubator at 37°C, 5% CO<sub>2</sub>
</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Centrifuge for 1.5 mL microcentrifuge tubes</td>
<td>Eppendorf 5427 R</td>
<td>N/A</td>
</tr>
<tr>
<td>Tecan F500</td>
<td>Plate reader</td>
<td>N/A</td>
</tr>
<tr>
<td>384-well white Flat Bottom low-volume microplate</td>
<td>PerkinElmer</td>
<td>Cat# 6008280</td>
</tr>
<tr>
<td>Plate sealing polyester films</td>
<td>VWR</td>
<td>Cat# 391-1250</td>
</tr>
</tbody>
</table>
</section>
<section>
<h2 id="materials-and-equipment">Materials and equipment</h2>
<table id="undtbl1">
<caption>10× phosphate buffered saline (PBS)</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaCl</td>
<td>1.4 M</td>
<td>81.8 g</td>
</tr>
<tr>
<td>KCl</td>
<td>27 mM</td>
<td>2.01 g</td>
</tr>
<tr>
<td>Na<sub>2</sub>HPO<sub>4</sub>
</td>
<td>100 mM</td>
<td>14.2 g</td>
</tr>
<tr>
<td>KH<sub>2</sub>PO<sub>4</sub>
</td>
<td>18 mM</td>
<td>2.45 g</td>
</tr>
<tr>
<td>ddH<sub>2</sub>O</td>
<td>n/a</td>
<td>To 1 L</td>
</tr>
<tr>
<td><b>Total</b></td>
<td><b>n/a</b></td>
<td><b>1 L</b></td>
</tr>
</tbody>
</table>
<div class="note">
<span class="note-title">Note:</span> The 10× PBS solution should be filtered using a 0.22 μm filter or autoclaved prior to use. Solution can be stored at 20°C–22°C for up to 1 month.</div>
<table id="undtbl2">
<caption>1× phosphate buffered saline (PBS)</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>10× PBS solution</td>
<td>1×</td>
<td>100 mL</td>
</tr>
<tr>
<td>ddH<sub>2</sub>O</td>
<td>n/a</td>
<td>900 mL</td>
</tr>
<tr>
<td><b>Total</b></td>
<td><b>n/a</b></td>
<td><b>1 L</b></td>
</tr>
</tbody>
</table>
<div class="note">
<span class="note-title">Note:</span> 1× PBS solution can be stored at 4°C for up to 1 week.</div>
<table id="undtbl3">
<caption>Complete DMEM cell culture medium</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dulbecco's Modified Eagle Medium (DMEM)</td>
<td>n/a</td>
<td>445 mL</td>
</tr>
<tr>
<td>Fetal bovine serum</td>
<td>10 %</td>
<td>50 mL</td>
</tr>
<tr>
<td>Penicilin / streptomicin</td>
<td>1 %</td>
<td>5 mL</td>
</tr>
<tr>
<td><b>Total</b></td>
<td><b>n/a</b></td>
<td><b>500 mL</b></td>
</tr>
</tbody>
</table>
<div class="note">
<span class="note-title">Note:</span> Medium should be stored at 4°C for up to 2 months.</div>
<div class="alternatives">
<span class="alternatives-title">Alternatives:</span> We usually buy sterile cell culture medium bottles, but the medium can also be prepared from powder. In this case, after preparing the medium it should be filtered using a 0.22 μm filter prior to use.</div>
<table id="undtbl4">
<caption>Transfection solution</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaCl (5 M)</td>
<td>150 mM</td>
<td>1.5 mL</td>
</tr>
<tr>
<td>ddH<sub>2</sub>O</td>
<td>n/a</td>
<td>48.5 mL</td>
</tr>
<tr>
<td><b>Total</b></td>
<td><b>n/a</b></td>
<td><b>50 ML</b></td>
</tr>
</tbody>
</table>
<div class="note">
<span class="note-title">Note:</span> Solution can be stored at stored at 4°C for up to 1 month.</div>
<table id="undtbl5">
<caption>TagLite buffer 1×</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>TagLite labelling medium 5×</td>
<td>1×</td>
<td>1 mL</td>
</tr>
<tr>
<td>ddH<sub>2</sub>O</td>
<td>n/a</td>
<td>4 mL</td>
</tr>
<tr>
<td><b>Total</b></td>
<td><b>n/a</b></td>
<td><b>5 mL</b></td>
</tr>
</tbody>
</table>
<div class="note">
<span class="note-title">Note:</span> Prepare fresh TagLite buffer before each experiment. The final volume to be prepared will depend on the number of data points and should be calculated in advance.</div>
<table id="undtbl6">
<caption>SNAP substrate labeling solution</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lumi4-tb substrate stock (0.1 mM)</td>
<td>100 nM</td>
<td>5 μL</td>
</tr>
<tr>
<td>TagLite labelling medium 1×</td>
<td>n/a</td>
<td>5 mL</td>
</tr>
<tr>
<td><b>Total</b></td>
<td><b>n/a</b></td>
<td><b>5 mL</b></td>
</tr>
</tbody>
</table>
<div class="note">
<span class="note-title">Note:</span> Prepare fresh SNAP substrate solution before each experiment. The final volume to be prepared will depend on the number of data points and should be calculated in advance.</div>
<table id="undtbl7">
<caption>Spike(RBD) working solution</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spike(RBD) stock (37.6 μM)</td>
<td>3.5 μM</td>
<td>4.7 μL</td>
</tr>
<tr>
<td>TagLite labelling medium 1×</td>
<td>n/a</td>
<td>45.3 μL</td>
</tr>
<tr>
<td><b>Total</b></td>
<td><b>n/a</b></td>
<td><b>50 μL</b></td>
</tr>
</tbody>
</table>
<div class="note">
<span class="note-title">Note:</span> Prepare fresh working solution before each experiment. The final volume to be prepared will depend on the number of data points and should be calculated in advance.</div>
<table id="undtbl8">
<caption>Spike(RBD)-d2 working solution</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spike(RBD)-d2 stock (11 μM)</td>
<td>35 nM</td>
<td>3.2 μL</td>
</tr>
<tr>
<td>TagLite labelling medium 1×</td>
<td>n/a</td>
<td>996.8 μL</td>
</tr>
<tr>
<td><b>Total</b></td>
<td><b>n/a</b></td>
<td><b>1 mL</b></td>
</tr>
</tbody>
</table>
<div class="note">
<span class="note-title">Note:</span> Prepare fresh working solution before each experiment. The final volume to be prepared will depend on the number of data points and should be calculated in advance.</div>
</section>
<section>
<h2 id="step-by-step-method-details">Step-by-step method details</h2>
<h3 id="sec3.1">HEK293T cells seeding – Day 1</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 30 min</div>
<p>To obtain HEK293T cells expressing SNAP-ACE2, cells are transiently transfected using transfection reagents.</p>
<div class="alternatives">
<span class="alternatives-title">Alternatives:</span> stable cell lines expressing SNAP-ACE2 can be used.</div>
<ol>
<li>From the stock culture of HEK293T cells, remove the cell culture medium and add 5 mL of sterile PBS to wash the cells.</li>
<li>Remove the PBS and add 1 mL trypsin/EDTA solution.</li>
<li>Incubate at 37°C in the cell culture incubator for 2–5 min.</li>
<li>Add 9 mL of complete DMEM medium and resuspend the cells.</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> Pipette the medium with cells up-and-down using a 10 mL pipette to better detach and dissociate the cells.</div>
<ol start="5">
<li>Collect the cell suspension in a 15 mL conical tube.</li>
<li>Take an aliquot of 10 μL of the cell suspension in a microcentrifuge tube to count the number of cells.</li>
<li>Spin down the 15 mL tube containing the cells at 180×<i>g</i> for 5 min.</li>
<li>Meanwhile, mix the 10 μL cell suspension aliquot with 10 μL trypan blue solution and transfer the 20 μL into a cell counting slide.</li>
<li>Count live cells manually with a hemocytometer or with an automated cell counter to determine the cell density.
<ol type="a">
<li>Exclude from the counting trypan blue-stained dead cells.</li>
<li>Calculate the required volume of cell suspension to obtain 2 × 10<sup>6</sup> cells / mL.</li>
</ol>
</li>
<li>Following the centrifugation, aspirate the supernatant.</li>
<li>Resuspend the cell pellet in the proper volume of complete DMEM medium calculated to obtain 2 × 10<sup>6</sup> cells / mL.</li>
<li>Seed 1 mL of cell suspension solution in a new 10 cm cell culture dish containing at least 9 mL of complete DMEM medium.</li>
<li>Incubate cells for 18–24 h at 37°C in a CO<sub>2</sub> (5%) incubator to allow cells to recover and attach to the plate.</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> Transfection can also be done in cells seeded in smaller dishes (i.e. 6-well plates) if the experimental design does not require a high number of cells (low number of data points).</div>
<h3 id="sec3.2">Cell transfection – Day 2</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 30 min</div>
<div class="note">
<span class="note-title">Note:</span> This step is skipped if a stable cell line expressing SNAP-ACE2 is used.</div>
<div class="alternatives">
<span class="alternatives-title">Alternatives:</span> The protocol shown here is for the JetPEI transfection reagent following the manufacturer’s instructions (Polyplus-transfection; Ilkirch, France). Other transfection reagents can be used and the respective manufacturer’s protocol should be followed. <a href="#sec6.1">Troubleshooting 1</a>
</div>
<ol start="14">
<li>Prepare the transfection solution containing the SNAP-ACE2 plasmid.
<ol type="a">
<li>Prepare one microcentrifuge tube per well to be transfected and mix 250 μL 150 mM NaCl with 5 μg plasmid DNA coding for SNAP-ACE2.</li>
<li>In another microcentrifuge tube, add 15 μL of JetPEI reagent to 250 μL NaCl (ratio 1:3 DNA: JetPEI). If several plates are to be transfected, multiply the volume by the number of plates.</li>
<li>Transfer 250 μL of the JetPEI-NaCl solution into the microcentrifuge tube containing the DNA.</li>
<li>Incubate for 15 min, at 20°C–22°C.</li>
</ol>
</li>
<li>Distribute the 500 μL of transfection solution, dropwise, all over the cells that are to be transfected.</li>
<li>Place the plate back in the incubator (37°C, 5% CO<sub>2</sub>) and allow cells to incubate for 48 h.</li>
</ol>
<div class="critical">
<span class="critical-title">Critical:</span> Cells should not exceed 70% confluency before transfecting to assure an optimal transfection rate. We found that an incubation time of 48 h (post-transfection) is optimal for the expression and plasma membrane translocation of membrane proteins.</div>
<div class="note">
<span class="note-title">Note:</span> If performing the TR-FRET assay in the low-throughput format or with adherent cells, the transfected cells can be plated 24 h post-transfection (Day 3) into white 96-well plates at a density of 0.5 × 10<sup>5</sup> cells/well. Cells are then incubated for another 24 h before starting the TR-FRET assay (Day 4).</div>
<h3 id="sec3.3">Fluorescent labelling of SNAP-ACE2 – Day 4</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 1.5 h</div>
<p>This step consists in the covalent labelling of the N-terminal SNAP-tagged human ACE2 expressed at the cell surface of transfected cells with the TR-FRET-compatible terbium (Tb) fluorophore. The Lumi4-Tb SNAP substrate is a suicide substrate of the SNAP enzyme labelled with a terbium fluorophore (<a href="#bib4">Keppler et al., 2003</a>).</p>
<ol start="17">
<li>Prepare Lumi4-Tb SNAP substrate solution at 100 nM by adding 5 μL of the stock solution (0.1 mM) into 5 mL of Tag-Lite buffer 1×.</li>
<li>Remove the cell culture medium and add 5 mL sterile PBS to wash the cells.</li>
<li>Remove the PBS and add the 5 mL Lumi4-Tb SNAP substrate solution.</li>
<li>Incubate the plate at 20°C–22°C for 1 h.</li>
<li>Remove the labeling solution and add 3 mL sterile PBS to wash the cells.</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> PBS solution used for the washing steps can be supplemented with 1 mM CaCl<sub>2</sub> and 0.5 mM MgCl<sub>2</sub> to prevent detaching the cells.</div>
<ol start="22">
<li>Remove the PBS and repeat the washing step with PBS.</li>
<li>Remove the PBS and repeat the washing step with TagLite buffer 1×.</li>
<li>Remove TagLite buffer and add 1 mL of cell dissociation solution.</li>
<li>Detach and dissociate the cells by pipetting up-and-down and collect them in a 1.5 mL microcentrifuge tube.</li>
<li>Spin down the 1.5 mL tube containing the cells at 1500×<i>g</i> for 5 min.</li>
<li>Remove the supernatant and add 1 mL of TagLite buffer 1× to resuspend the cell pellet.</li>
<li>Verify successful SNAP labeling
<ol type="a">
<li>Add 10 μL of the cell suspension per well in two wells (duplicate) of a white 384-well plate.</li>
<li>Read the plate in a plate reader using the filter configuration compatible with the excitation and emission spectra of the Terbium fluorophore. Settings in the TECAN F500 plate reader to read the Tb donor signal are shown in <a href="#tbl1">Table 1</a>.
<table id="tbl1">
<caption>Table 1. Donor (Tb) reading settings using TECAN F500 plate reader</caption>
<thead>
<tr>
<th colspan="2">Reading settings in Tecan F500 plate reader</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excitation wavelength</td>
<td>340 nm</td>
</tr>
<tr>
<td>Emission wavelength</td>
<td>620 nm</td>
</tr>
<tr>
<td>Excitation bandwidth</td>
<td>20 nm</td>
</tr>
<tr>
<td>Emission bandwidth</td>
<td>10 nm</td>
</tr>
<tr>
<td>Gain</td>
<td>Optimal</td>
</tr>
<tr>
<td>Number of flashes</td>
<td>10</td>
</tr>
<tr>
<td>Integration time</td>
<td>500 μs</td>
</tr>
<tr>
<td>Lag time</td>
<td>150 μs</td>
</tr>
</tbody>
</table>
</li>
</ol>
</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> The Tb fluorophore emits at multiple wavelengths and it is, therefore, suitable as a donor fluorophore also for acceptors emitting at the green spectrum (see Cisbio website - <a href="https://fr.cisbio.eu/content/htrf-technology/">https://fr.cisbio.eu/content/htrf-technology/</a>). In both cases, the Tb (donor) signal is measured at 620 nm.</div>
<div class="critical">
<span class="critical-title">Critical:</span> ACE2 labeling is essential for the TR-FRET assay. Only proceed to the next step if successful labeling of ACE2 is obtained. Use mock-transfected cells to access the background of Tb signal. From our experience, 5 to 10-fold signal-to-background ratio indicates successful SNAP labelling. An example of Tb donor signal in SNAP-ACE2-expressing cells and in mock-transfected cells is shown in <a href="#fig2">Figure 2</a>. <a href="#sec6.3">Troubleshooting 2</a>
</div>
<figure id="fig2"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/1243-Fig2.jpg" alt="Fig2.jpg">
<figcaption>
<div class="figcaption-title">Figure 2. Example of Tb donor signal</div>
<p>Tb donor signal (at 620 nm) obtained in SNAP-ACE2-expressing cells and in mock-transfected cells, in two replicates of each group (well 1, well 2). In this experiment, HEK293T cells were transfected with 500 ug of SNAP-ACE2 construct in one well of a 6-well plate. Forty-eight hours post-transfection, cells were labelled with Lumi4-Tb substrate as described, and 10 μL of the cell suspension was used to measure the resulting Tb donor signal in the Tecan F500 plate reader. Gain was set to “optimal” and corresponded to a value of 92 in this experiment.</p>
</figcaption>
</figure>
<h3 id="sec3.4">TR-FRET assay</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 2–3 h</div>
<ol start="29">
<li>Distribute 10 μL per well of the Tb-labeled SNAP-ACE2 cells into a white 384-well plate. It is recommended to use an electronic pipette to increase speed and accuracy.</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> Labelled cells can be diluted by a factor of 3–5 in TagLite buffer if high Tb signal is obtained. Optimal cell density and/or Tb signal will depend on the cell surface expression of SNAP-ACE2 and can be tested in advance to define the best conditions to obtain a low background signal and high signal-to-noise ratio. For example, in the experiment shown in <a href="#fig2">Figure 2</a>, cells could be used at a dilution of 3.5 times, which would result in a Tb signal still 20-fold higher than background (i.e. mock-transfected cells).</div>
<div class="optional">
<span class="optional-title">Optional:</span> Remaining labeled cells can be frozen and stored (−20°C) to be used later, within 2 weeks. Cell suspension solution should be divided into aliquots to avoid repeated freeze-thaw cycles.</div>
<ol start="30">
<li>Add 2 μL of test compound at the desired concentration to the “test” wells.</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> Working solution should be 7× concentrated.</div>
<ol start="31">
<li>In the “NSB” wells, add 2 μL of 3.5 μM non-labeled RBD (final concentration of 0.5 μM).</li>
<li>In the “BKG” and “TB” wells, add 2 μL of 1× TagLite buffer.
<ol type="a">
<li>Seal the plate with a plate sealing film and incubate at 20°C–22°C for 15 min.</li>
</ol>
</li>
<li>Add 2 μL of Tag-lite buffer to “BKG” wells.</li>
<li>Add 2 μL of 35 nM RBD-d2 solution to all wells (final concentration of 5 nM), except in the “BKG” wells.
<ol start="2" type="a">
<li>Incubate the plate at 20°C–22°C for 2 h.</li>
</ol>
</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> An overview of the order of TR-FRET reagents to be added to the different wells is shown in <a href="#tbl2">Table 2</a>.</div>
<ol start="35">
<li>Read the plate in a TR-FRET-compatible plate reader. Settings in the TECAN F500 plate reader to read the TR-FRET signal are shown in <a href="#tbl3">Table 3</a>.
<table id="tbl2">
<caption>Table 2. Volume and order of reagent distribution at each step of the TR-FRET assay in a 384-well plate</caption>
<thead>
<tr>
<th> </th>
<th>Background (“BKG”)</th>
<th>Total binding (“TB”)</th>
<th>Non-specific binding (“NSB”)</th>
<th>Test compounds (“Test”)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cells</td>
<td>10 μL</td>
<td>10 μL</td>
<td>10 μL</td>
<td>10 μL</td>
</tr>
<tr>
<td>TagLite buffer 1×</td>
<td>2 μL</td>
<td>2 μL</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Test compounds (7×)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>2 μL</td>
</tr>
<tr>
<td>Non-labeled RBD (7×)</td>
<td>–</td>
<td>–</td>
<td>2 μL</td>
<td>–</td>
</tr>
<tr>
<td colspan="5">Seal the plate and incubate at 20°C–22°C for 15 min</td>
</tr>
<tr>
<td>TagLite buffer 1×</td>
<td>2 μL</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>RBD-d2 (7×)</td>
<td>–</td>
<td>2 μL</td>
<td>2 μL</td>
<td>2 μL</td>
</tr>
<tr>
<td colspan="5">Seal the plate and incubate at 20°C–22°C for 2 h</td>
</tr>
<tr>
<td colspan="5">Read the plate in a TR-FRET-compatible plate reader</td>
</tr>
</tbody>
</table>
<table id="tbl3">
<caption>Table 3. TR-FRET reading settings using TECAN F500 plate reader</caption>
<thead>
<tr>
<th colspan="2">Reading settings in Tecan F500 plate reader</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="2">Fluorescence 1: d2</td>
</tr>
<tr>
<td>Excitation wavelength</td>
<td>340 nm</td>
</tr>
<tr>
<td>Emission wavelength</td>
<td>665 nm</td>
</tr>
<tr>
<td>Excitation bandwidth</td>
<td>20 nm</td>
</tr>
<tr>
<td>Emission bandwidth</td>
<td>8 nm</td>
</tr>
<tr>
<td>Gain</td>
<td>Optimal</td>
</tr>
<tr>
<td>Number of flashes</td>
<td>10</td>
</tr>
<tr>
<td>Integration time</td>
<td>500 μs</td>
</tr>
<tr>
<td>Lag time</td>
<td>150 μs</td>
</tr>
<tr>
<td colspan="2">Fluorescence 2: Tb</td>
</tr>
<tr>
<td>Excitation wavelength</td>
<td>340 nm</td>
</tr>
<tr>
<td>Emission wavelength</td>
<td>620 nm</td>
</tr>
<tr>
<td>Excitation bandwidth</td>
<td>20 nm</td>
</tr>
<tr>
<td>Emission bandwidth</td>
<td>10 nm</td>
</tr>
<tr>
<td>Gain</td>
<td>Optimal<sup><a href="#tblfn1">∗</a></sup>
</td>
</tr>
<tr>
<td>Number of flashes</td>
<td>10</td>
</tr>
<tr>
<td>Integration time</td>
<td>500 μs</td>
</tr>
<tr>
<td>Lag time</td>
<td>150 μs</td>
</tr>
</tbody>
</table>
<p id="tblfn1" class="table-footnote"><sup>∗</sup>When reading TR-FRET multiple times (every hour or in a kinetics mode, for example) the Gain of the donor signal should be set to a fixed value corresponding to the value obtained in the first reading.</p>
</li>
</ol>
<div class="critical">
<span class="critical-title">Critical:</span> Perform at least triplicates for each data point (see <a href="#fig1">Figure 1</a> for an example of plate template).</div>
<div class="alternatives">
<span class="alternatives-title">Alternatives:</span> other TR-FRET-compatible plate readers, such as EnVision (PerkinElmer) can also be used.</div>
<div class="optional">
<span class="optional-title">Optional:</span> The TR-FRET signal being stable, several reads can be performed at different time points, once every hour, for example, until equilibrium is reached. In this case, it is important to fix the “Gain” setting of the donor channel (620 nm) to a fixed value in order to be able to compare the different readings.</div>
<div class="alternatives">
<span class="alternatives-title">Alternatives:</span> Kinetics parameters can also be determined with slight changes in the protocol, as previously shown (<a href="#bib2">Cecon et al., 2021</a>). To determine association kinetics parameters, read the TR-FRET signal continuously during 2 h, starting immediately after adding RBD-d2. To determine dissociation kinetics parameters, allow binding of RBD-d2 to reach equilibrium (2 h incubation) and only then add excess of non-labelled RBD to displace bound RBD-d2 and read the TR-FRET signal continuously during 2 h, starting immediately after adding non-labelled RBD.</div>
<h3 id="sec3.5">Data analysis</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 30 min</div>
<ol start="36">
<li>Once the reading is finished, export the results file as .csv file.</li>
<li>Calculate the TR-FRET signal, which is the ratio of the acceptor (RBD-d2, measured at 665 nm) over the donor (Tb-ACE2, measured at 620 nm) signals for each well. For convenience, the ratio is multiplied by 10000. An example of a TR-FRET data sheet result is shown in <a href="#tbl4">Table 4</a>. The specific signal for each well can be obtained by subtracting the NSB signal from the TR-FRET signal.
<table id="tbl4">
<caption>Table 4. Example of raw fluorescence signal data (in triplicates) and TR-FRET ratio calculation</caption>
<thead>
<tr>
<th> </th>
<th>Signal 665 nm</th>
<th>Signal 620 nm</th>
<th>Ratio × 10<sup>4</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Background (“BKG”)</td>
<td>7083</td>
<td>91025</td>
<td>778</td>
</tr>
<tr>
<td>Background (“BKG”)</td>
<td>7443</td>
<td>95990</td>
<td>775</td>
</tr>
<tr>
<td>Background (“BKG”)</td>
<td>6256</td>
<td>82306</td>
<td>760</td>
</tr>
<tr>
<td>Total Binding (“TB”)</td>
<td>131850</td>
<td>99294</td>
<td>13279</td>
</tr>
<tr>
<td>Total Binding (“TB”)</td>
<td>135114</td>
<td>102504</td>
<td>13181</td>
</tr>
<tr>
<td>Total Binding (“TB”)</td>
<td>131898</td>
<td>101650</td>
<td>12976</td>
</tr>
<tr>
<td>Non-specific binding (“NSB”)</td>
<td>5486</td>
<td>58405</td>
<td>939</td>
</tr>
<tr>
<td>Non-specific binding (“NSB”)</td>
<td>6842</td>
<td>94789</td>
<td><b>722</b></td>
</tr>
<tr>
<td>Non-specific binding (“NSB”)</td>
<td>6369</td>
<td>83848</td>
<td>760</td>
</tr>
</tbody>
</table>
</li>
</ol>
<p class="math-ml"><math> <mtext>TR-FRET</mtext> <mspace></mspace> <mtext>signal</mtext> <mo>=</mo> <mfrac> <mrow> <mtext>Signal</mtext> <mspace></mspace> <mn>665</mn> <mspace></mspace> <mtext>nm </mtext> </mrow> <mrow> <mtext>Signal</mtext> <mspace></mspace> <mn>620</mn> <mspace></mspace> <mtext>nm</mtext> </mrow> </mfrac> <mo>×</mo> <msup> <mn>10</mn> <mn>4</mn> </msup> </math></p>
<p class="math-ml"><math> <mrow> <mtext>Specific</mtext> <mspace></mspace> <mtext>Signal</mtext> <mspace></mspace> <mrow> <mo>(</mo> <mtext>for</mtext> <mspace></mspace> <mtext>each</mtext> <mspace></mspace> <mtext>well</mtext> <mo>)</mo> </mrow> <mo>=</mo> <mtext>TR</mtext> <mo>-</mo> <mtext>FRET</mtext> <mspace></mspace> <mtext>signal</mtext> <mspace></mspace> <mo>−</mo> <mspace></mspace> <mtext>NSB</mtext> </mrow> </math></p>
<div class="note">
<span class="note-title">Note:</span> By performing the ratio, the TR-FRET is normalized to the donor signal, counteracting thus any potential differences in the number of cells per well. Some plate readers allow to integrate the calculation equation, providing thus the final TR-FRET signal data.</div>
<div class="note">
<span class="note-title">Note:</span> the raw data value are arbitrary units and, therefore, it is not possible to perform direct comparison of raw data between different plate readers. If such comparison is envisioned, the fold-change of the specific signal should be used.</div>
<ol start="38">
<li>Use a spreadsheet or statistics software package to calculate the arithmetic mean of the triplicates.</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> Check that the Tb signal is homogeneous between wells to identify potential outliers. <a href="#sec6.5">Troubleshooting 3</a>
</div>
<ol start="39">
<li>Normalize the data to 0–100% scale by setting the mean of the “TB” group as 100% and the mean of the “NSP” group as 0 % using a statistics software package like GraphPad Prism.</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> As the raw values (fluorescence signal) are given in arbitrary units, the normalization to a percentage scale allows to pool together independent repetitions of the experiment.</div>
<ol start="40">
<li>Use a statistics software package like GraphPad Prism to calculate standard deviations and statistical significance and to plot the data in a graph.</li>
</ol>
</section>
<section>
<h2 id="expected-outcomes">Expected outcomes</h2>
<p>A successful TR-FRET experiment should show a clear difference between “TB” and “NSB” signals, with “NSB” signal being similar or very close to the “BKG” signal (<a href="#sec6.7">troubleshooting 4</a>; <a href="#sec6.9">troubleshooting 5</a>). The amplitude of the signal depends on the distance between the two fluorophores. In the TR-FRET mode for ACE2/RBD, a high “TB” TR-FRET signal with a low BKG is observed, as it can be easily competed with excess of non-labelled RBD, conferring a high amplitude of the specific signal (”TB”-“NSB”). The ratio between the TR-FRET signals for “TB” and “NSB” (“TB”/”NSB”) can be expected to range between 5 (at Kd concentration of RBD-d2) to 30-fold (at saturating concentrations of RBD-d2). Of note, the “TB” TR-FRET signal is proportional to the concentration of RBD-d2, up to a saturation limit that we have detected to occur at approximately 100 nM of RBD-d2 (<a href="#bib2">Cecon et al., 2021</a>). In the case that the objective of the assay is to screen the efficacy of candidate compounds to interfere with the RBD-ACE2 interaction, the concentration of RBD-d2 used should be around its affinity (Kd), i.e., low nanomolar range (for example, 5 nM), as described in this protocol. Positive interfering compounds are the ones giving a specific TR-FRET signal significantly lower than the specific signal of RBD-d2 alone (i.e., without “test” compound). A representative bar graph of an expected result of an experiment including all the groups mentioned in this protocol (“BKG”, “TB”, “NSB” and “Test”) is shown in <a href="#fig3">Figure 3</a>.</p>
<figure id="fig3"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/1243-Fig3.jpg" alt="Fig3.jpg">
<figcaption>
<div class="figcaption-title">Figure 3. Example of expected result</div>
<p>Representative bar graph of an experiment testing the effect of a nanobody against RBD (10 μg/mL) on RBD-d2 binding to ACE2. Data are expressed as mean ± SD of triplicates. See <a href="#bib2">Cecon et al. (2021)</a> for information on the nanobody used.</p>
</figcaption>
</figure>
</section>
<section>
<h2 id="limitations">Limitations</h2>
<p>The protocol described here comprises an assay to detect the binding of RBD to ACE2. The choice of using the RBD domain of the spike protein was due to the reduced size of this peptide, compared to the full protein, which favors the proximity between the d2-fluorophore and the Tb-labelled ACE2. The assay has the advantage of providing a very high specific signal, being thus suitable to the identification of compounds interfering with this interaction. However, one cannot exclude that other regions of the Spike protein might be relevant for cell interaction and cell entry of SARS-CoV-2 virus. The use of d2-labeled full-length S1-S2 Spike protein for the TR-FRET assay is possible, as reported (<a href="#bib2">Cecon et al., 2021</a>), but the amplitude of the signal is significantly lower than that observed for the RBD-d2, reaching 2-fold the “NSB” values. Such difference is probably due to the bigger size of the S1-S2 spike protein, which might increase the distance between the fluorophores.</p>
<p>In addition, the use of recombinant proteins (RBD or S1-S2) may represent only a simplified model of SARS-CoV-2 interaction with cellular systems, as it has been described that the Spike protein is highly glycosylated and acts as a trimer (<a href="#bib7">Xu et al., 2021</a>). Therefore, inhibitory compounds identified using the TR-FRET assay described here need to be validated using additional techniques such as cellular or <i>in vivo</i> infection models with SARS-CoV-2 virus.</p>
<p>Finally, the TR-FRET signal is correlated to the distance between the acceptor and donor fluorophores. Therefore, a change in TR-FRET signal could reflect either a conformational change within the protein complex or an increase in association or dissociation of RBD and ACE2. Compounds of interest identified by this method can have an impact on those processes and would need to be characterized further for their exact properties.</p>
</section>
<section>
<h2 id="troubleshooting">Troubleshooting</h2>
<h3 id="sec6.1">Problem 1</h3>
<p>No detectable SNAP-ACE2 expression (<a href="#sec3.2">cell transfection – Day 2</a> step 14).</p>
<h3 id="sec6.2">Potential solution</h3>
<p>Transfection efficiency can be indirectly accessed at step 28, when verifying the SNAP labelling. If low transfection rate is suspected to occur, transfection efficiency can be tested using different transfection reagents and verified by direct methods such as Western Blot (using antibodies against ACE2 or against the Flag-tag) or fluorescence imaging (using microscopy-compatible SNAP fluorophores for SNAP labeling).</p>
<h3 id="sec6.3">Problem 2</h3>
<p>No detectable SNAP-ACE2 labeling with Tb fluorophore (<a href="#sec3.3">fluorescent labelling of SNAP-ACE2 – Day 4</a> step 28).</p>
<h3 id="sec6.4">Potential solution</h3>
<p>Verify that the cells were efficiently transfected with SNAP-ACE2 construct by using techniques like western blot or immunofluorescence imaging.</p>
<p>Make sure cells are not overconfluent at the moment of labelling and verify that they do not detach during the washing steps after labelling.</p>
<h3 id="sec6.5">Problem 3</h3>
<p>Too much variation between the wells for the Tb fluorescent signal (<a href="#sec3.5">data analysis</a> step 38).</p>
<h3 id="sec6.6">Potential solution</h3>
<p>Check the precision of the pipette used for the step of distribution of the cells in the 384-well plate. Make sure that the same pool of Lumi4-Tb-labelled cells is used for all wells in the experiment.</p>
<h3 id="sec6.7">Problem 4</h3>
<p>No detectable differences between BKG and TB signals in the d2 fluorescent channel (<a href="#expected-outcomes">expected outcomes</a>).</p>
<h3 id="sec6.8">Potential solution</h3>
<p>Decrease the cell density used in the assay in order to decrease BKG signal. Make sure RBD-d2 is freshly prepared and added to the corresponding wells. Increase the RBD-d2 concentration or perform a saturation curve to verify that RBD-d2 is working as expected (see saturation curve in <a href="#bib2">Cecon et al., 2021</a>).</p>
<h3 id="sec6.9">Problem 5</h3>
<p>No significant difference between TR-FRET signals for “TB” and “NSB” (<a href="#expected-outcomes">expected outcomes</a>).</p>
<h3 id="sec6.10">Potential solution</h3>
<p>Make sure that the concentration of non-labelled RBD is at least 100× higher than the concentration of RBD-d2. Check (by visual inspection) for the presence of aggregates in the RBD stock solution, as the real concentration of the protein might be reduced if insoluble aggregates are present.</p>
</section>
<section>
<h2 id="references">References</h2>
<p id="bib1">Bazin, H., Trinquet, E., and Mathis, G. (2002). Time resolved amplification of cryptate emission: a versatile technology to trace biomolecular interactions. J. Biotechnol. <i>82</i>, 233-250. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00730-9/sref1">View at publisher</a></p>
<p id="bib2">Cecon, E., Burridge, M., Cao, L., Carter, L., Ravichandran, R., Dam, J., and Jockers, R. (2021). SARS-COV-2 spike binding to ACE2 in living cells monitored by TR-FRET. Cell Chem. Biol. <a class="external-link" href="https://doi.org/10.1016/j.chembiol.2021.06.008">https://doi.org/10.1016/j.chembiol.2021.06.008</a></p>
<p id="bib3">Degorce, F., Card, A., Soh, S., Trinquet, E., Knapik, G.P., and Xie, B. (2009). HTRF: a technology tailored for drug discovery - a review of theoretical aspects and recent applications. Curr. Chem. Genomics <i>3</i>, 22-32. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00730-9/sref3">View at publisher</a></p>
<p id="bib4">Keppler, A., Gendreizig, S., Gronemeyer, T., Pick, H., Vogel, H., and Johnsson, K. (2003). A general method for the covalent labeling of fusion proteins with small molecules in vivo. Nat. Biotechnol. <i>21</i>, 86-89. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00730-9/sref4">View at publisher</a></p>
<p id="bib5">Mathis, G. (1995). Probing molecular interactions with homogeneous techniques based on rare earth cryptates and fluorescence energy transfer. Clin. Chem. <i>41</i>, 1391-1397. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00730-9/sref5">View at publisher</a></p>
<p id="bib6">Schneider, C.A., Rasband, W.S., and Eliceiri, K.W. (2012). NIH Image to ImageJ: 25 years of image analysis. Nat. Methods <i>9</i>, 671-675. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00730-9/sref6">View at publisher</a></p>
<p id="bib7">Xu, C., Wang, Y., Liu, C., Zhang, C., Han, W., Hong, X., Hong, Q., Wang, S., Zhao, Q., Yang, Y., et al. (2021). Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. Sci. Adv. <i>7</i>, eabe5575. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00730-9/sref7">View at publisher</a></p>
</section>
<section>
<h2 id="article-info">Article info</h2>
<h3>Resource availability</h3>
<h4>Lead contact</h4>
<p>Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Ralf Jockers (<a href="mailto:ralf.jockers@inserm.fr">ralf.jockers@inserm.fr</a>).</p>
<h4>Materials availability</h4>
<p>Plasmids generated in this study have been deposited to Addgene (SNAP-ACE2, id: 178592).</p>
<h4>Data and code availability</h4>
<p>This paper does not report original datasets.</p>
<p>This paper does not report original code.</p>
<p>Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.</p>
<h3>Acknowledgments</h3>
<p>We thank all the members of the Jockers lab for the discussion at the initial phase of the project. This work was supported by <a href="https://doi.org/10.13039/501100001665">Agence Nationale de la Recherche</a> (ANR-RA-COVID-19 [ANR-20-COV4-0001 to R.J., ANR-19-CE16-0025-01 to R.J., ANR-16-CE18-0013 to J.D.]), Institut National de la Sante et de la Recherche Medicale (Inserm), Center National de la Recherche Scientifique (CNRS). R.J. was supported by the Fondation pour la Recherche Medicale (Equipe <a href="https://doi.org/10.13039/501100002915">FRM</a> DEQ20130326503) and La <a href="https://doi.org/10.13039/501100004099">Ligue Contre le Cancer</a> N/Ref: RS19/75-127 and E.C. by the <a href="https://doi.org/10.13039/501100003750">Association France Alzheimer</a> (grant no. 2042).</p>
<h3>Author contributions</h3>
<p>All authors contributed to the conceptualization and to the writing of the manuscript.</p>
<h3>Declaration of interests</h3>
<p>The authors declare no competing interests.</p>
</section>
</article>